Literature DB >> 8550799

Assessment of growth hormone (GH) secretion in men with adult-onset GH deficiency compared with that in normal men--a clinical research center study.

H B Baum1, B M Biller, L Katznelson, D S Oppenheim, D R Clemmons, K B Cannistraro, D A Schoenfeld, S A Best, A Klibanski.   

Abstract

It is not known how patients who acquire GH deficiency (GHD) in adulthood differ in measures of GH secretion from normal adults. To characterize measures of GH secretion in such patients compared to those in normal subjects, we studied 23 men (median age, 51 yr; range, 32-62 yr) with adult-onset pituitary disease, defined as GH-deficient based on having no detectable GH response to two pharmacological agents, and 17 normal men. Patients less than 50 yr old received insulin (0.1 U/kg, i.v.) and clonidine (0.15 mg, orally), whereas those 50 yr of age or older as well as normal controls received arginine (30 g, i.v.) and clonidine. Patients were compared to normal men by investigating GH sampling every 10 min for 24 h and serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein 2 (IGFBP-2), IGFBP-3, and GH-binding protein. Frequent venous sampling of GH was analyzed in terms of mean 24-h levels, pooled 24-h GH, mean levels over the 12 h between 2000-0800 h (mean overnight GH level), and pulse analysis (pulses per 24 h and pulse amplitude) by the Pulsar computer program. Although there were significant differences between the two groups for almost all measures of GH secretion, overlap between the groups was always present. GH levels measured using a highly sensitive chemiluminescence assay on 24-h pools derived from frequent sampling displayed the least overlap between the two groups, as only 2 of 17 normal controls overlapped with the GHD patients. The pooled 24-h GH level using this technique was significantly lower in patients with GHD than in controls (0.117 +/- 0.021 vs. 0.861 +/- 0.098 micrograms/L; P < 0.0001). In the analysis of frequent GH sampling using a standard immunoradiometric assay, mean overnight GH levels provided the best separation between the two groups, as all 23 patients had values of 0.6 microgram/L or less, and 13 of 17 normal controls had values greater than 0.6 microgram/L. The mean overnight GH level in patients was 0.6 +/- 0.0 microgram/L compared to 1.0 +/- 0.1 microgram/L in controls (P < 0.0001). The mean 24-h GH level in patients was 0.5 +/- 0.0 microgram/L compared to 0.8 +/- 0.1 microgram/L in normal controls (P < 0.0001). GH pulse frequency and pulse amplitude were also reduced in patients with GHD compared to those in normal controls [1.7 +/- 0.5 vs. 5.1 +/- 0.5 pulses/24 h (P < 0.0001) and 0.6 +/- 0.1 vs. 2.8 +/- 0.4 microgram/L (P < 0.0001), respectively]. The mean serum IGF-I level was significantly lower in patients with GHD than in normal controls (106.7 +/- 8.0 vs. 218.7 +/- 16.7 microgram/L; P < 0.0001). Three of 23 patients overlapped with control values. Mean serum levels of IGFBP-3 and the serum IGF-I/IGFBP-2 ratio were also significantly lower in patients than in controls, but values overlapped substantially. We conclude that overlap occurs on measures of GH secretion between normal men and men identified as GH deficient despite a stringent definition of GHD. The best separation was obtained using pooled 24-h GH levels determined by a highly sensitive chemiluminescence assay.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8550799     DOI: 10.1210/jcem.81.1.8550799

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Growth hormone deficiency in the adult.

Authors:  M Doga; S Bonadonna; M Gola; G Mazziotti; A Giustina
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 2.  Hypopituitarism as a consequence of brain tumours and radiotherapy.

Authors:  Ken H Darzy; Stephen M Shalet
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Plasma IGF-I is a useful marker of growth hormone deficiency in adults.

Authors:  J P Span; G F Pieters; C G Sweep; L M Swinkels; A G Smals
Journal:  J Endocrinol Invest       Date:  1999-06       Impact factor: 4.256

Review 4.  Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.

Authors:  E Ghigo; G Aimaretti; E Arvat; F Camanni
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

5.  Growth hormone and sex steroid effects on serum glucose, insulin, and lipid concentrations in healthy older women and men.

Authors:  Thomas Münzer; S Mitchell Harman; John D Sorkin; Marc R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2009-07-14       Impact factor: 5.958

6.  The pituitary stalk effect: is it a passing phenomenon?

Authors:  Marvin Bergsneider; Leili Mirsadraei; William H Yong; Noriko Salamon; Michael Linetsky; Marilene B Wang; David L McArthur; Anthony P Heaney
Journal:  J Neurooncol       Date:  2014-02-19       Impact factor: 4.130

Review 7.  Hypopituitarism following radiotherapy.

Authors:  Ken H Darzy; Stephen M Shalet
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 8.  Diagnosis and management of adult growth hormone deficiency.

Authors:  K K Ho
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.925

9.  Evaluation of permanent growth hormone deficiency (GHD) in young adults with childhood onset GHD: a multicenter study.

Authors:  Merih Berberoğlu; Zeynep Sıklar; Feyza Darendeliler; Sükran Poyrazoğlu; Sükran Darcan; Pınar Işgüven; Aysun Bideci; Gönül Ocal; Rüveyde Bundak; Bilgin Yüksel; Ilknur Arslanoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2008-08-05

Review 10.  IGF-I measurements in the diagnosis of adult growth hormone deficiency.

Authors:  Anita Y M Kwan; Mark L Hartman
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.